Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?

NCT ID: NCT04347876

Last Updated: 2020-04-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-11

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is no evidence that the Bacille Calmette-Guérin vaccine (BCG) protects people against infection with COVID-19 virus. Two clinical trials addressing this question are underway, and WHO will evaluate the evidence when it is available. In the absence of evidence, WHO does not recommend BCG vaccination for the prevention of COVID-19. WHO continues to recommend neonatal BCG vaccination in countries or settings with a high incidence of tuberculosis. There is experimental evidence from both animal and human studies that the BCG vaccine has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance is unknown

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 BCG Vaccination

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

COVID-19 positive with positive tuberculin test

Tuberculin test

Intervention Type DIAGNOSTIC_TEST

Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination

Group B

COVID-19 positive with negative tuberculin test

Tuberculin test

Intervention Type DIAGNOSTIC_TEST

Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tuberculin test

Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* COVID-19 positive cases admitted to hospitals in Upper Egypt

Exclusion Criteria

* None
Minimum Eligible Age

12 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Aliae AR Mohamed Hussein

Professor of Pulmonology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AssiutU

Asyut, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Aliae AR Mohamed-Hussein

Role: primary

+201222302352

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AssiutU12

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BCG Vaccination to Prevent COVID-19
NCT04632537 WITHDRAWN PHASE3
Trial of Two Strains of BCG
NCT02447536 COMPLETED PHASE4
Trial to Compare Two Strains of BCG
NCT04383925 COMPLETED PHASE4